Why Septerna stock is on investors’ radar

Septerna (SEPN) stock has drawn attention after recent trading, with the share price closing at US$24.71 and short term returns showing mixed moves over the past week and month.

That recent uptick in Septerna’s share price, with a 1 day share price return of 2.40% and 7 day share price return of 4.00%, sits against a weaker year to date share price return of an 11.69% decline, even as the 1 year total shareholder return is around 2.6x.

If you are comparing Septerna’s move with other biotech ideas, it can help to scan a wider set of companies and see how they stack up against 32 healthcare AI stocks

With Septerna trading at US$24.71 and analyst targets pointing higher, yet recent returns looking mixed, the key question for you is simple: is this stock still overlooked, or is the market already pricing in its future growth?

Preferred Price-to-Sales of 24.1x: Is it justified?

On a P/S basis, Septerna looks expensive versus both its peers and the broader US Pharmaceuticals industry, even with the stock at $24.71 after recent trading.

P/S compares the company’s market value to its revenue and is often used for early stage or unprofitable biotechs where earnings are not yet available. For Septerna, the current P/S of 24.1x is well above the US Pharmaceuticals industry average of 5.5x and the peer average of 8.2x. Revenue over the past year is reported at $45.951 million and the company remains loss making with net income of a $48.879 million loss.

This large premium suggests investors are paying several times more per dollar of revenue than for typical sector peers. Relative to an estimated fair P/S ratio of 5.6x, the current level is also materially higher. This indicates a valuation that could move closer to that fair ratio level if sentiment or expectations change.

Result: Price-to-Sales of 24.1x (OVERVALUED)

However, you also need to weigh catalysts that could challenge this setup, including Septerna’s ongoing losses of US$48.879 million and a revenue growth rate of 5.35%.

Next Steps

Given the mixed signals so far, it makes sense to review the full picture yourself and weigh both the upside and the downside. Start by reviewing the 1 key reward and 2 important warning signs.

Looking for more investment ideas?

If Septerna has your attention, do not stop here. Broaden your watchlist with other stocks that fit clear, focused criteria so you are not relying on a single story.

• Spot potential turnaround opportunities early by scanning 24 elite penny stocks with strong financials that already pair tiny share prices with stronger financial footing.
• Prioritize quality at a reasonable price by reviewing the 44 high quality undervalued stocks that combine solid cash flows with balance sheets many investors overlook.
• Seek consistency and staying power by checking the 74 resilient stocks with low risk scores that score well on resilience instead of just chasing the latest headline mover.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.